CL2018000320A1 - Coadyuvantes basados en aceite (divisional de solicitud 201600650) - Google Patents

Coadyuvantes basados en aceite (divisional de solicitud 201600650)

Info

Publication number
CL2018000320A1
CL2018000320A1 CL2018000320A CL2018000320A CL2018000320A1 CL 2018000320 A1 CL2018000320 A1 CL 2018000320A1 CL 2018000320 A CL2018000320 A CL 2018000320A CL 2018000320 A CL2018000320 A CL 2018000320A CL 2018000320 A1 CL2018000320 A1 CL 2018000320A1
Authority
CL
Chile
Prior art keywords
oil based
based adjuvants
application division
same
division
Prior art date
Application number
CL2018000320A
Other languages
English (en)
Inventor
Paul Joseph Dominowski
Lauren Wilmes
Dennis L Foss
Kaori Mohr
Guillermo Gallo
John Morgan Hardham
Richard Lee Krebs
Sandra Ann Marie Lightle
Suman Mahan
Sangita Mediratta
Duncan Mwangi
Sharath K Rai
Sarah A Salmon
Shaunak Vora
David George Emslie Smith
Michael Christopher Fontaine
Julie Lydia Fitzpatrick
William Donachie
Anita Dorota Jaglarz
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CL2018000320A1 publication Critical patent/CL2018000320A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA DIVERSAS FORMULACIONES QUE COMPRENDEN COMBINACIONES DE OLIGONUCLEÁTIDOS INMUNOESTIMULANTES, VEHÍCULOS POLICATIÓNICOS, ESTEROLES, SAPONINAS, AMINAS CUATERNARIAS, AGONISTAS DE TLR-3, GLICOLIPIDOS Y MPL-A O ANÁLOGOS DEL MISMO EN EMULSIONES EN ACEITE, EL USO CE LAS MISMAS EN PREPARACIONES DE COMPOSICIONES INMUNOGÉNICAS Y VACUNAS Y EL USO DE LAS MISMAS EN EL TRATAMIENTO DE ANIMALES.</p>
CL2018000320A 2013-09-19 2018-02-05 Coadyuvantes basados en aceite (divisional de solicitud 201600650) CL2018000320A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361879959P 2013-09-19 2013-09-19

Publications (1)

Publication Number Publication Date
CL2018000320A1 true CL2018000320A1 (es) 2018-06-08

Family

ID=51663499

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2016000650A CL2016000650A1 (es) 2013-09-19 2016-03-18 Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento.
CL2018000320A CL2018000320A1 (es) 2013-09-19 2018-02-05 Coadyuvantes basados en aceite (divisional de solicitud 201600650)
CL2018000319A CL2018000319A1 (es) 2013-09-19 2018-02-05 Coadyuvantes basados en aceite (divisional de solicitud 201600650)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2016000650A CL2016000650A1 (es) 2013-09-19 2016-03-18 Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2018000319A CL2018000319A1 (es) 2013-09-19 2018-02-05 Coadyuvantes basados en aceite (divisional de solicitud 201600650)

Country Status (16)

Country Link
US (6) US10117921B2 (es)
EP (2) EP3046580A2 (es)
JP (7) JP6586083B2 (es)
KR (4) KR101943171B1 (es)
CN (4) CN105764525A (es)
AU (5) AU2014321369B2 (es)
BR (1) BR112016005948A2 (es)
CA (4) CA3174897C (es)
CL (3) CL2016000650A1 (es)
MX (3) MX386918B (es)
NZ (3) NZ733383A (es)
PH (1) PH12016500456A1 (es)
RU (1) RU2730011C2 (es)
UA (2) UA121200C2 (es)
WO (3) WO2015042449A2 (es)
ZA (3) ZA201601840B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA121097C2 (uk) * 2012-12-28 2020-04-10 Бьорінгер Інгельхайм Ветмедіка Гмбх Імуногенна композиція, що містить антигени мікоплазм
UA121200C2 (uk) * 2013-09-19 2020-04-27 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
US11318200B2 (en) * 2013-11-26 2022-05-03 Zoetis Services Llc Methods and compositions for induction of immune response
US10251950B2 (en) 2014-07-11 2019-04-09 Zoetis Services Llc Vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
EP4248992A3 (en) 2015-01-16 2023-12-27 Zoetis Services LLC Foot-and-mouth disease vaccine
EP3250228A1 (en) * 2015-01-27 2017-12-06 3M Innovative Properties Company Alum-containing coating formulations for microneedle vaccine patches
KR102085968B1 (ko) * 2015-07-20 2020-03-06 조에티스 서비시즈 엘엘씨 리포솜 보조제 조성물
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
CN106421775B (zh) * 2015-08-12 2020-12-01 普莱柯生物工程股份有限公司 一种疫苗用佐剂及含该佐剂的疫苗组合物和其应用
CA3010977A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
US10946085B2 (en) 2016-02-15 2021-03-16 Hipra Scientific, S.L.U. Streptococcus uberis extract as an immunogenic agent
WO2017165366A1 (en) 2016-03-21 2017-09-28 South Dakota Board Of Regents Orf virus-based platform for vaccine delivery
KR20220100725A (ko) 2016-06-02 2022-07-15 조에티스 서비시즈 엘엘씨 감염성 기관지염에 대한 백신
JP2020502204A (ja) * 2016-12-22 2020-01-23 インターベット インターナショナル ベー． フェー． 改善された有効性を有するエイメリアワクチン
KR101996538B1 (ko) * 2017-02-13 2019-07-04 단디바이오사이언스 주식회사 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
GB201718251D0 (en) * 2017-11-03 2017-12-20 Univ Sydney Vaccine Compositions
US20210008195A1 (en) * 2017-12-20 2021-01-14 Zoetis Services Llc Vaccines against hendra and nipah virus infection
CN108553479A (zh) * 2018-04-03 2018-09-21 南京大学 阳离子修饰的琼脂糖和核酸药物组合物及制备方法和应用
CN108853493A (zh) * 2018-07-26 2018-11-23 中国人民解放军陆军军医大学 麦冬皂苷d及其纳米乳在制备疫苗佐剂中的应用
CA3107319A1 (en) 2018-07-27 2020-01-30 Research Development Foundation Chimeric immunogenic polypeptides
CN110967482B (zh) * 2018-09-30 2023-04-07 重庆市畜牧科学院 一种山羊化脓隐秘杆菌感染检测试剂盒及其检测方法
CN109675028A (zh) * 2019-03-01 2019-04-26 龙阔（苏州）生物工程有限公司 疫苗佐剂及其制备方法和应用及猪繁殖与呼吸综合征疫苗
KR102285977B1 (ko) 2019-03-15 2021-08-05 대한민국 오일 에멀젼과 병용 투여 가능한 면역증강용 보조물질 및 이를 포함하는 구제역 백신 조성물
CA3146842A1 (en) 2019-07-12 2021-01-21 Research Development Foundation Ehrlichia vaccines and immunogenic compositions
US12514917B2 (en) * 2019-07-15 2026-01-06 South Dakota Board Of Regents Senecavirus A virus strains and immunogenic compositions therefrom
WO2021021778A1 (en) * 2019-07-30 2021-02-04 Phibro Animal Health Corporation A composition for mucosal administration to avians
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
TWI884296B (zh) * 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CN112611864B (zh) * 2020-12-03 2024-03-12 重庆市畜牧科学院 筛分病菌模型的系统及筛分方法
WO2022123070A1 (en) * 2020-12-11 2022-06-16 Acm Biolabs Pte Ltd Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
CN114015621B (zh) * 2021-12-13 2022-04-26 云南农业大学 一种降解α-茄碱的谷氨酸杆菌GH202103菌株及其制备方法和应用
EP4683663A1 (en) * 2023-03-21 2026-01-28 Indian Council Of Agricultural Research Vaccine compositions and methods for control of foot and mouth disease
EP4731640A1 (en) 2023-06-26 2026-04-29 Research Development Foundation Immunoreactive peptides
CN116747312B (zh) * 2023-07-21 2025-08-08 辽宁成大生物股份有限公司 一种疫苗冻干保护剂、制剂及制备方法
CN119925590A (zh) * 2025-04-08 2025-05-06 北京华诺泰生物医药科技有限公司 一种mpl复合佐剂及其制备方法和应用

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
EP0273512B1 (en) 1986-12-19 1991-02-27 Duphar International Research B.V Stabilised adjuvant suspension comprising dimethyl dioctadecyl ammonium bromide
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
RU1615918C (ru) 1989-05-22 1995-07-09 Всероссийский научно-исследовательский институт защиты животных Адъювант
GB8921470D0 (en) * 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
ZA978434B (en) * 1996-09-27 1998-03-26 Akzo Nobel Nv Inactivated vaccines.
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
US20100267012A1 (en) * 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
BR9809426A (pt) 1997-04-30 2000-06-13 Merieux Oravax Composição de vacina anti-helicobacter para uso pela via sistêmica subdiafragmática e método de imunização mucosal/parenteral combinado
WO1998051278A2 (en) 1997-05-14 1998-11-19 Inex Pharmaceuticals Corporation High efficiency encapsulation of charged therapeutic agents in lipid vesicles
WO1998055495A2 (en) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1999058118A2 (en) 1998-05-14 1999-11-18 Cpg Immunopharmaceuticals Gmbh METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
DK1733735T3 (en) 1998-05-22 2017-06-19 Ottawa Hospital Res Inst Methods and products for the induction of mucosal immunity
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
EP1104306B1 (en) 1998-08-10 2006-01-11 Antigenics Inc. Compositions of cpg and saponin adjuvants and methods of use thereof
AUPP807399A0 (en) * 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP2286792A1 (en) 1999-02-26 2011-02-23 Novartis Vaccines and Diagnostics, Inc. Microemulsions with an adsorbent surface, comprising a microdroplet emulsion
WO2000061184A2 (en) 1999-04-08 2000-10-19 Glenn Gregory M Dry formulation for transcutaneous immunization
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
ATE275727T1 (de) 1999-04-29 2004-09-15 Coley Pharm Gmbh Screening nach modulatoren der funktion von immunstimulatorischer dna
EP1322655B1 (en) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US20030086938A1 (en) 2000-02-21 2003-05-08 Jensen Martin Roland Novel methods for down-regulation of amyloid
JP2003531915A (ja) 2000-05-01 2003-10-28 ハイブリドン・インコーポレイテッド ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
HU229642B1 (en) * 2000-10-18 2014-03-28 Glaxosmithkline Beecham Biolog S A Vaccines against cancers
ATE439372T1 (de) * 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic Nukleinsäuren und proteine von gruppen a und b- streptokokken
ES2307568T3 (es) 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
EP1347775B1 (en) 2001-01-05 2016-11-30 Valneva Austria GmbH Uses for polycationic compounds as vaccine adjuvants
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
JP2004527524A (ja) 2001-04-05 2004-09-09 カイロン コーポレイション 非経口初回抗原刺激後の粘膜追加免疫
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
CA2448031A1 (en) 2001-05-21 2002-11-28 Intercell Ag Method for stabilising of nucleic acids
WO2002102307A2 (en) 2001-06-15 2002-12-27 Ribapharm Nucleoside vaccine adjuvants
PT1474067E (pt) 2001-07-02 2008-11-14 Pfizer Prod Inc Vacinação numa dose com mycoplasma hyopneumoniae
WO2003004051A2 (en) 2001-07-02 2003-01-16 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
JP2005518343A (ja) 2001-08-03 2005-06-23 メダレックス， インク． 新規なｐｇｃ−１イソフォームおよびその使用媒介型免疫治療を向上させるためのその使用
CA2456328C (en) 2001-08-07 2015-05-26 Dynavax Technologies Corporation Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
US20030138434A1 (en) 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
ES2314099T3 (es) 2001-08-17 2009-03-16 Coley Pharmaceutical Gmbh Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
HUP0401077A3 (en) 2001-08-28 2004-10-28 Pfizer Prod Inc Mycoplasma bovis challenge model, methods for administering m. bovis and methods for inducing pneumonic lung lesions
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
US20030119774A1 (en) 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
JP2005508945A (ja) 2001-10-06 2005-04-07 メリアル リミテッド Ｃｐｇ配合物及び関連方法
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
EP1441763A2 (en) 2001-11-07 2004-08-04 Inex Pharmaceuticals Corp. Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
CA2452909A1 (en) 2001-12-07 2003-06-13 Intercell Ag Immunostimulatory oligodeoxynucleotides
AU2003203079B8 (en) 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
WO2003070190A2 (en) 2002-02-19 2003-08-28 Syntherica Corporation Surrogate antibodies and methods of preparation and use thereof
CA2480775C (en) 2002-04-04 2016-05-31 Coley Pharmaceutical Gmbh Immunostimulatory g,u-containing oligoribonucleotides
AU2003262379A1 (en) 2002-04-16 2003-11-03 Auburn University TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH
AU2003219383B2 (en) 2002-04-22 2010-08-26 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
KR100456681B1 (ko) 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
JP2005528899A (ja) 2002-05-28 2005-09-29 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗原提示細胞の生成方法
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US20040009949A1 (en) 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
SE0201701D0 (sv) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
AU2003263963A1 (en) 2002-08-01 2004-02-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
US20060107872A1 (en) 2002-11-05 2006-05-25 Hong Chen Method and apparatus for producing calcium silicate hydrate
HRP20050660A2 (en) 2003-01-29 2006-02-28 Pfizer Products Inc. Canine vaccines against bordetella bronchiseptica
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
RU2351362C2 (ru) 2003-03-26 2009-04-10 Цитос Байотекнолоджи Аг КОНЪЮГАТЫ ПЕПТИДА Melan-A, АНАЛОГА ВИРУСОПОДОБНОЙ ЧАСТИЦЫ
AU2004226591B2 (en) 2003-04-04 2009-06-04 Zoetis Services Llc Microfluidized oil-in-water emulsions and vaccine compositions
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
JP5393978B2 (ja) 2004-04-05 2014-01-22 ゾエティス・ピー・エルエルシー マイクロ流動化された水中油型乳剤及びワクチン組成物
ATE406874T1 (de) * 2004-07-07 2008-09-15 Statens Seruminstitut Zusammensetzungen und verfahren zur stabilisierung von adjuvans-formulierungen auf lipid-basis unter verwendung von glykolipiden
US7749520B2 (en) 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
WO2006106424A2 (en) 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
ES2425576T3 (es) 2006-01-26 2013-10-16 Zoetis P Llc Composiciones coadyuvantes glucolipídicas novedosas
WO2007125940A1 (ja) * 2006-04-25 2007-11-08 Kyowa Hakko Kogyo Co., Ltd. ネコノミ成虫由来ポリペプチド
CN101517082B (zh) * 2006-09-27 2014-01-22 科勒制药有限责任公司 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
US20080292663A1 (en) 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
EP2023143A1 (en) * 2007-08-06 2009-02-11 Boehringer Ingelheim Vetmedica Gmbh Immunogenic streptococcus proteins
US8703153B2 (en) * 2008-06-16 2014-04-22 Prokarium Ltd. Salmonella vectored vaccines against Chlamydia and methods of use
WO2009156960A2 (en) * 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions
GB0818231D0 (en) * 2008-10-06 2008-11-12 Univ Nottingham Composition
CN101721698B (zh) 2008-10-24 2014-04-02 法罗斯疫苗公司 抗口蹄疫疫苗组合物及其制备和应用
BRPI1005919B1 (pt) 2009-02-27 2021-06-22 Toray Industries, Inc Composição imunogênica
EP3165531B1 (en) * 2010-03-12 2020-11-25 Children's Medical Center Corporation Immunogenic composition, vaccine, and uses thereof
EP2575878B1 (en) * 2010-05-28 2018-06-13 Zoetis Belgium S.A. Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
US8765141B2 (en) 2010-07-01 2014-07-01 The United States Of America, As Represented By The Secretary Of Agriculture Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host
CN101954080B (zh) 2010-09-21 2013-11-06 中国农业科学院兰州兽医研究所 一种猪口蹄疫苗用的复合分子型佐剂及其制造方法
PT2670432T (pt) * 2011-02-04 2021-05-04 Zoetis Services Llc Composições imunogénicas de bordetella bronchiseptica
ES2639122T3 (es) * 2011-05-13 2017-10-25 Zoetis Services Llc Composiciones inmunogénicas de glucoproteína G de virus Hendra y Nipah
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
GB201111183D0 (en) 2011-06-30 2011-08-17 Animal Health Inst Peptide
HUE051277T2 (hu) * 2012-11-16 2021-03-01 United Biomedical Inc Szintetikus peptiden alapuló sürgõsségi vakcina ragadós száj- és körömfájás (FMD) ellen
CN103083663B (zh) 2013-02-04 2014-12-10 江苏省农业科学院 一种免疫增强剂、灭活疫苗及其制备方法
RU2662764C2 (ru) * 2013-03-07 2018-07-30 Кейн Байотек Инк. Антимикробные антибиопленочные композиции и способы их применения
US10357470B2 (en) * 2013-03-07 2019-07-23 Kane Biotech Inc. Antimicrobial-antibiofilm compositions and methods of use thereof
CA2907571A1 (en) 2013-03-26 2014-10-02 The Pirbright Institute Stabilised fmdv capsids
AU2014315353A1 (en) * 2013-09-05 2016-03-10 Zoetis Services Llc Hendra and Nipah virus G glycoprotein immunogenic compositions
UA121200C2 (uk) * 2013-09-19 2020-04-27 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
CN104013955B (zh) * 2014-06-18 2016-02-24 中国科学院过程工程研究所 一种不含表面活性剂的水包油乳液及其用途
RU2593718C1 (ru) 2015-03-16 2016-08-10 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Вакцина инактивированная эмульсионная против ящура типов а, о, азия-1

Also Published As

Publication number Publication date
CN109675029A (zh) 2019-04-26
AU2022275399B2 (en) 2025-05-08
PH12016500456A1 (en) 2016-05-16
US12121576B2 (en) 2024-10-22
KR101943171B1 (ko) 2019-01-29
US20210170013A1 (en) 2021-06-10
UA130246C2 (uk) 2025-12-31
MX2021012346A (es) 2021-11-04
JP6586083B2 (ja) 2019-10-02
CA3060664A1 (en) 2015-03-26
WO2015042423A3 (en) 2016-07-28
JP7189410B2 (ja) 2022-12-14
EP3049105B1 (en) 2020-12-30
CA2924526A1 (en) 2015-03-26
KR20160057465A (ko) 2016-05-23
JP7181847B2 (ja) 2022-12-01
AU2022268311A1 (en) 2022-12-15
JP7675048B2 (ja) 2025-05-12
US20160193318A1 (en) 2016-07-07
AU2014321369A1 (en) 2016-03-17
US20150140034A1 (en) 2015-05-21
KR20180024030A (ko) 2018-03-07
AU2014321369B2 (en) 2020-04-16
EP3049105A2 (en) 2016-08-03
BR112016005948A2 (pt) 2017-09-26
AU2025202708A1 (en) 2025-05-08
JP2020007341A (ja) 2020-01-16
MX386918B (es) 2025-03-19
NZ733383A (en) 2022-12-23
EP3046580A2 (en) 2016-07-27
WO2015042369A2 (en) 2015-03-26
JP2016534977A (ja) 2016-11-10
WO2015042449A2 (en) 2015-03-26
US10117921B2 (en) 2018-11-06
NZ757210A (en) 2022-12-23
CL2016000650A1 (es) 2016-11-18
RU2730011C2 (ru) 2020-08-14
UA121200C2 (uk) 2020-04-27
US10744192B2 (en) 2020-08-18
US10953080B2 (en) 2021-03-23
KR102257743B1 (ko) 2021-05-28
CA3005608C (en) 2020-06-30
MX2016003658A (es) 2016-06-24
CA3174897A1 (en) 2015-03-26
JP2022001581A (ja) 2022-01-06
CN109675026A (zh) 2019-04-26
WO2015042423A2 (en) 2015-03-26
CL2018000319A1 (es) 2018-06-08
KR20190009840A (ko) 2019-01-29
CA3174897C (en) 2025-10-07
ZA201903401B (en) 2024-09-25
JP7751438B2 (ja) 2025-10-08
CA3005608A1 (en) 2015-03-26
ZA201601840B (en) 2022-09-28
AU2020202147A1 (en) 2020-04-16
JP2019167356A (ja) 2019-10-03
WO2015042449A3 (en) 2015-10-08
JP2021073191A (ja) 2021-05-13
KR20200039025A (ko) 2020-04-14
US20250108103A1 (en) 2025-04-03
ZA201903400B (en) 2024-09-25
WO2015042369A3 (en) 2015-07-02
JP2018203770A (ja) 2018-12-27
AU2022268311B2 (en) 2025-01-23
AU2022275399A1 (en) 2023-01-05
US11701415B2 (en) 2023-07-18
CN109675025A (zh) 2019-04-26
RU2019128164A (ru) 2019-10-10
CN105764525A (zh) 2016-07-13
US20190038737A1 (en) 2019-02-07
RU2016109925A3 (es) 2018-04-02
MX2021005619A (es) 2021-08-11
RU2019128165A (ru) 2019-10-10
NZ717594A (en) 2017-07-28
JP6667704B2 (ja) 2020-03-18
RU2016109925A (ru) 2017-10-24
US20240000913A1 (en) 2024-01-04
AU2020202147B2 (en) 2022-12-08
JP2022121437A (ja) 2022-08-19

Similar Documents

Publication Publication Date Title
CL2018000319A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
MX2017001279A (es) Usos y composiciones de la flagelina.
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
BR112017004524A2 (pt) pirrolopirimidinas para uso na infecção pelo vírus da gripe
MX2015016627A (es) Vacuna para la malaria.
MX2017003121A (es) Formulaciones de anticuerpos.
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
MX2018013409A (es) Métodos y dispositivos para la preparación de agentes de contraste de ultrasonido.
CL2020001464A1 (es) Péptidos antimicrobianos y métodos para usarlos.
PH12015000376B1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX391152B (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
MX2017001396A (es) Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo.
MX2021005910A (es) Formulacion de proteina de alta concentracion.
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
EA201791437A1 (ru) Композиции микросфер c инкапсулированным в липиде газом и соответствующие способы
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
AR105728A1 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
PL406972A1 (pl) Sposób otrzymywania kompozycji zawierającej klotrimazol oraz kompozycja farmaceutyczna uzyskana tym sposobem